Azione PTGX PROTAGONIST THERAPEUTICS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Protagonist Therapeutics, Inc.

Azioni

PTGX

US74366E1029

Mercato chiuso - Nasdaq
Altri mercati azionari
 19:00:00 03/07/2024 		Variaz. 5gg Var. 1 gen.
34,5 USD -0,26% Grafico intraday di Protagonist Therapeutics, Inc. +8,63% +50,46%
28/06 Protagonist Therapeutics entrerà a far parte dell'indice S&P SmallCap 600 MT
14/06 Protagonist Therapeutics, Inc. riporta i risultati aggiornati a lungo termine dello studio REVIVE di Fase 2 su Rusfertide al Congresso EHA2024, mostrando un controllo duraturo dell'ematocrito CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!
Registrazione 100% gratuita
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P Composite 1500
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 3000 Value Index
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 2500 Value Index
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell Small Cap Comp Value Index
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 2000 Value Index
Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) dropped from Russell 3000E Value Index
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024
Protagonist Therapeutics to Join S&P SmallCap 600
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing
Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Protagonist Therapeutics: Q1 Earnings Snapshot
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione PTGX
  4. Notizie Protagonist Therapeutics, Inc.
  5. Altre lingue